文献速递高血压血脂与心血管预防

高血压治疗研究策略:回顾性真实世界数据的价值

Research strategies in treatment of hypertension: value of retrospective real-life data.
PubMed 文献 · Eur Heart J · 2022-01-01

本综述讨论随机对照试验(RCT)数据在日常临床管理中的适用性局限,指出改良RCT设计(如实用性试验)仅部分克服这些局限,而真实世界研究可填补RCT遗留的许多空白并具有重要补充价值。重点阐述基于医疗利用数据库回顾性分析的真实世界研究方法,详述其多重优势与挑战,并强调其在高血压等心血管危险因素治疗评估中的贡献。

要点

  • RCT数据用于日常临床管理存在适用性局限,真实世界研究具重要补充价值。
  • 医疗利用数据库可低成本长期提供药物疗法等信息,覆盖一般人群至临床重要亚组。
  • 该方法可评估治疗依从性低和治疗惰性等RCT难以充分评价的医疗实践现象。

核心结论

  • 真实世界研究可填补RCT遗留的许多证据空白,与试验证据具有重要互补价值。
  • 基于医疗利用数据库的回顾性分析能提供RCT无法获得的真实世界心血管治疗信息。

研究设计与样本

  • 本综述讨论RCT数据的适用性局限及真实世界研究的补充价值,聚焦基于医疗利用数据库的回顾性分析方法。

主要发现

  • 医疗利用数据库可低成本长期提供多种医疗问题信息,尤其药物治疗信息,覆盖一般人群至临床重要亚组。
  • 该数据可评估治疗的预后方面(通过住院和病死率数据)及医疗实践相关现象如低治疗依从性和治疗惰性。
  • 电子格式数据可快速获得结果,有助于紧急情况下的及时决策。

临床怎么用

  • 可利用医疗利用数据库回顾性分析评估真实世界中心血管药物治疗的预后和医疗实践相关现象。

局限性

  • 该方法存在适应证混杂、错分和选择偏倚等潜在缺陷,可通过适宜分析手段部分最小化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review will discuss the limitations of data collected by RCTs in relation to their applicability to daily life clinical management. It will then argue that these limitations are only partially overcome by modifications of RCT design and conduction (e.g. 'pragmatic trials') while being substantially attenuated by real-life-derived research, which can fill many gaps left by trial-collected evidence and have thus an important complementary value. The focus will be on the real-life research approach based on the retrospective analysis of the now widely available healthcare utilization databases (formerly known as administrative databases), which will be discussed in detail for their multiple advantages as well as challenges. Emphasis will be given to the potential of these databases to provide low-cost information over long periods on many different healthcare issues, drug therapies in particular, from the general population to clinically important subgroups, including (i) prognostic aspects of treatments implemented at the medical practice level via hospitalization and fatality data and (ii) medical practice-related phenomena such as low treatment adherence and therapeutic inertia (unsatisfactorily evaluated by RCTs). It will also be mentioned that thanks to the current availability of these data in electronic format, results can be obtained quickly, helping timely decisions under emergencies. The potential shortcomings of this approach (confounding by indication, misclassification, and selection bias) will also be discussed along with their possible minimization by suitable analytic means. Finally, examples of the contributions of studies on hypertension and other cardiovascular risk factors will be offered based on retrospective healthcare utilization databases that have provided information on real-life cardiovascular treatments unavailable via RCTs.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. Eur Heart J. 2022. PMID: 35134885. doi:10.1093/eurheartj/ehab899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。